212 related articles for article (PubMed ID: 9703859)
41. The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group.
González Barón M; Espinosa E; Feliu J; Ordóñez A; Zamora P; de Castro J; García Girón C; García Alfonso P; Garrido P; Belón J; Lomas M
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):109-12. PubMed ID: 9348581
[TBL] [Abstract][Full Text] [Related]
42. [Clinical results of advanced gastric cancer patients treated with oxaliplatin-containing regimen].
Zhang WM; Xu GH; Ju AP; Zheng YT; Jiang Q
Ai Zheng; 2003 Dec; 22(12):1346-8. PubMed ID: 14693066
[TBL] [Abstract][Full Text] [Related]
43. Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen.
Raderer M; Kornek GV; Hejna MH; Miholic J; Weinlaender G; Brodowicz T; Fiebiger WC; Valencak JB; Scheithauer W
Eur J Cancer; 1998 Jun; 34(7):1128-30. PubMed ID: 9849466
[TBL] [Abstract][Full Text] [Related]
44. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Hofheinz RD; Hartung G; Samel S; Hochhaus A; Pichlmeier U; Post S; Hehlmann R; Queisser W
Onkologie; 2002 Jun; 25(3):255-60. PubMed ID: 12119460
[TBL] [Abstract][Full Text] [Related]
45. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
Kikuyama S; Inada T; Miyakita M; Ogata Y
Jpn J Clin Oncol; 1998 May; 28(5):314-7. PubMed ID: 9703858
[TBL] [Abstract][Full Text] [Related]
47. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
49. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
50. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
51. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Tsavaris NB; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekois D; Tsetis A; Klonaris C
Am J Clin Oncol; 1996 Oct; 19(5):517-21. PubMed ID: 8823483
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
53. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
55. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
[TBL] [Abstract][Full Text] [Related]
56. Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma.
Schmitz SH; Voliotis DL; Schimke J; Diehl V
Oncology; 1994; 51(6):502-6. PubMed ID: 7970494
[TBL] [Abstract][Full Text] [Related]
57. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
58. Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Yen CC; Tung SL; Hsieh RK; Chiou TJ; Liu JH; Wang WS; Chen PM
Jpn J Clin Oncol; 1997 Oct; 27(5):316-20. PubMed ID: 9390208
[TBL] [Abstract][Full Text] [Related]
59. Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.
Chi KH; Chao Y; Chan WK; Lo SS; Chen SY; Yen SH; Chen KY; Wu CW; Lee SD; Lui WY
Br J Cancer; 1998 Jun; 77(11):1984-8. PubMed ID: 9667679
[TBL] [Abstract][Full Text] [Related]
60. Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer: results of a phase II trial.
Jäger E; Bernhard H; Klein O; Wächter B; Theiss F; Dippold W; Meyer zum Büschenfelde KH; Knuth A
Ann Oncol; 1995 Feb; 6(2):153-6. PubMed ID: 7540418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
